32 418

Cited 0 times in

Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial.

Authors
Park, DW; Kim, YH; Yun, SC; Kang, SJ; Lee, SW; Lee, CW; Park, SW; Seong, IW; Lee, JH; Tahk, SJ; Jeong, MH; Jang, Y; Cheong, SS; Yang, JY; Lim, DS; Seung, KB; Chae, JK; Hur, SH; Lee, SG; Yoon, J; Lee, NH; Choi, YJ; Kim, HS; Kim, KS; Hong, TJ; Park, HS; Park, SJ
Citation
Journal of the American College of Cardiology, 56(15):1187-1195, 2010
Journal Title
Journal of the American College of Cardiology
ISSN
0735-10971558-3597
Abstract
OBJECTIVES: The aim of this study was to evaluate the relative efficacy and safety of zotarolimus-eluting stents (ZES) in comparison with the established and widely used sirolimus- (SES) and paclitaxel-eluting stents (PES) in routine clinical practice.



BACKGROUND: Whether ZES might provide similar clinical and angiographic outcomes in a broad spectrum of patients compared with SES or PES is undetermined.



METHODS: We performed a single-blind, multicenter, prospectively randomized trial to compare ZES with SES and PES in 2,645 patients undergoing percutaneous coronary intervention. The primary end point was a composite of major adverse cardiac events (MACE) (death, myocardial infarction, and ischemia-driven target vessel revascularization) at 12 months. A noninferiority comparison (ZES vs. SES) and a superiority comparison (ZES vs. PES) were performed for the primary end point.



RESULTS: Baseline clinical and angiographic characteristics were similar in the 3 groups. At 12 months, the ZES group showed noninferior rates of MACE compared with the SES group (10.2% vs. 8.3%, p for noninferiority = 0.01, p for superiority = 0.17) and significantly fewer MACE than the PES group (10.2% vs. 14.1%, p for superiority = 0.01). The incidence of death or myocardial infarction was similar among the groups (ZES vs. SES vs. PES, 5.8% vs. 6.9% vs. 7.6%, respectively, p = 0.31). The incidence of stent thrombosis was significantly lower in the SES group (ZES vs. SES vs. PES, 0.7% vs. 0% vs. 0.8%, respectively, p = 0.02).



CONCLUSIONS: In this large-scale, practical randomized trial, the use of ZES resulted in similar rates of MACE compared with SES and in fewer MACE compared with PES at 12 months. (Comparison of the Efficacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions; NCT00418067).
MeSH terms
AgedCardiovascular Diseases/etiology/mortalityCoronary Restenosis/etiology/mortality*Drug-Eluting Stents/adverse effectsFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial Reperfusion/adverse effects/*instrumentationPaclitaxel/*administration & dosage/adverse effectsProspective StudiesSingle-Blind MethodSirolimus/*administration & dosage/adverse effects/*analogs & derivativesTreatment Outcome
DOI
10.1016/j.jacc.2010.03.086
PMID
20883925
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
AJOU Authors
탁, 승제
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse